|
1
|
Kang S: Psoriasis. In: Fitzpatrick's
Dermatology. 9th edition. Vol 1, McGraw-Hill Education, New York,
NY, pp457-494, 2019.
|
|
2
|
Porumb-Andrese E, Vâță D, Postolică R,
Stătescu L, Stătescu C, Grăjdeanu AI, Pătrașcu AI, Popescu IA and
Solovastru LG: Association between personality type, affective
distress profile and quality of life in patients with psoriasis vs.
patients with cardiovascular disease. Exp Ther Med. 18:4967–4973.
2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Batani A, Branisteanu DE, Ilie MA, Boda D,
Ianosi S, Ianosi G and Caruntu C: Assessment of dermal papillary
and microvascular parameters in psoriasis vulgaris using in vivo
reflectance confocal microscopy. Exp Ther Med. 15:1241–1246.
2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Taranu T, Toader MP and Esanu I: The
importance of dual dermatologic and psychiatric approach in
psychocutaneous disorders. Rom J Oral Rehab. 8:18–27. 2016.
|
|
5
|
Van de Kerkhof PC and Nestlé FO:
Psoriasis. In: Dermatology. Bolognia J, Schaffer J and Cerroni L
(eds). 4th edition. Vol 1, Elsevier, Philadelphia, pp138-158,
2017.
|
|
6
|
Maranduca MA, Hurjui LL, Branisteanu DC,
Serban DN, Branisteanu DE, Dima N and Serban IL: Skin-a vast organ
with immunological function (Review). Exp Ther Med. 20:18–23.
2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Laws PM and Warren RB: Psoriasis and
comorbidities. In: Advances in Psoriasis. Weinberg JM and Lebwohl M
(eds). Springer, Cham, pp363-397, 2021.
|
|
8
|
Hu SC and Lan CE: Psoriasis and
cardiovascular comorbidities: Focusing on severe vascular events,
cardiovascular risk factors and implications for treatment. Int J
Mol Sci. 18(2211)2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Masson W, Lobo M and Molinero G: Psoriasis
and cardiovascular risk: A comprehensive review. Adv Ther.
37:2017–2033. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Korman NJ: Management of psoriasis as a
systemic disease: What is the evidence? Br J Dermatol. 182:840–848.
2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Gelfand JM, Neimann AL, Shin DB, Wang X,
Margolis DJ and Troxel AB: Risk of myocardial infarction in
patients with psoriasis. JAMA. 296:1735–1741. 2006.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Gelfand JM, Dommasch ED, Shin DB, Azfar
RS, Kurd SK, Wang X and Troxel AB: The risk of stroke in patients
with psoriasis. J Invest Dermatol. 129:2411–2418. 2009.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ghazizadeh R, Shimizu H, Tosa M and
Ghazizadeh M: Pathogenic mechanisms shared between psoriasis and
cardiovascular disease. Int J Med Sci. 7:284–289. 2010.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Martinez-Moreno A, Ocampo-Candiani J and
Garza-Rodriguez V: Psoriasis and cardiovascular disease: A
narrative review. Korean J Fam Med. 42:345–355. 2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Jindal S and Jindal N: Psoriasis and
cardiovascular diseases: A literature review to determine the
causal relationship. Cureus. 10(e2195)2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Boehncke WH: Systemic inflammation and
cardiovascular comorbidity in psoriasis patients: Causes and
consequences. Front Immunol. 9(579)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Gisondi P, Bellinato F, Girolomoni G and
Albanesi C: Pathogenesis of chronic plaque psoriasis and its
intersection with cardio-metabolic comorbidities. Front Pharmacol.
11(117)2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Coumbe AG, Pritzker MR and Duprez DA:
Cardiovascular risk and psoriasis: Beyond the traditional risk
factors. Am J Med. 127:12–18. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Iorga A, Cunningham CM, Moazeni S,
Ruffenach G, Umar S and Eghbali M: The protective role of estrogen
and estrogen receptors in cardiovascular disease and the
controversial use of estrogen therapy. Biol Sex Differ.
8(33)2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sondermann W, Djeudeu Deudjui DA, Körber
A, Slomiany U, Brinker TJ, Erbel R and Moebus S: Psoriasis,
cardiovascular risk factors and metabolic disorders: Sex-specific
findings of a population-based study. J Eur Acad Dermatol Venereol.
34:779–786. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Garshick MS, Vaidean G, Nikain CA, Chen Y,
Smilowitz NR and Berger JS: Sex differences in the prevalence of
vascular disease and risk factors in young hospitalized patients
with psoriasis. Int J Womens Dermatol. 5:251–255. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Yamazaki F, Takehana K, Tanaka A, Son Y,
Ozaki Y and Tanizaki H: Relationship between psoriasis and
prevalence of cardiovascular disease in 88 Japanese patients. J
Clin Med. 10(3640)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Valaiyaduppu Subas S, Mishra V, Busa V,
Antony I, Marudhai S, Patel M and Cancarevic I: Cardiovascular
involvement in psoriasis, diagnosing subclinical atherosclerosis,
effects of biological and non-biological therapy: A literature
review. Cureus. 12(e11173)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Mocanu M, Toader MP, Rezus E and Taranu T:
Aspects concerning patient adherence to anti-TNFα therapy in
psoriasis: A decade of clinical experience. Exp Ther Med.
18:4987–4992. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Branisteanu DE, Voicu CM, Cretu A,
Dimitriu A, Luca MC and Salavastru CM: Adverse reactions of
biological therapy for psoriasis. Rev Med Chir Soc Med Nat Iasi.
119:38–44. 2015.PubMed/NCBI
|
|
26
|
Balanescu AR, Bojinca VC, Bojinca M,
Donisan T and Balanescu SM: Cardiovascular effects of methotrexate
in immune-mediated inflammatory diseases. Exp Ther Med.
17:1024–1029. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Mikhaylov D, Hashim PW, Nektalova T and
Goldenberg G: Systemic psoriasis therapies and comorbid disease in
patients with psoriasis: A review of potential risks and benefits.
J Clin Aesthet Dermatol. 12:46–54. 2019.PubMed/NCBI
|
|
28
|
Grechin C, Solovastru LG, Vata D, Patrascu
AI, Grajdeanu AI and Porumb-Andrese E: Inflammatory marker
alteration in response to systemic therapies in psoriasis. Exp Ther
Med. 20:42–46. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Elnabawi YA, Dey AK, Goyal A, Groenendyk
JW, Chung JH, Belur AD, Rodante J, Harrington CL, Teague HL, Baumer
Y, et al: Coronary artery plaque characteristics and treatment with
biologic therapy in severe psoriasis: Results from a prospective
observational study. Cardiovasc Res. 115:721–728. 2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Choi H, Uceda DE, Dey AK, Abdelrahman KM,
Aksentijevich M, Rodante JA, Elnabawi YA, Reddy A, Keel A,
Erb-Alvarez J, et al: Treatment of psoriasis with biologic therapy
is associated with improvement of coronary artery plaque Lipid-rich
necrotic core: Results from a prospective, observational study.
Circ Cardiovasc Imaging. 13(e011199)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wu JJ, Guérin A, Sundaram M, Dea K,
Cloutier M and Mulani P: Cardiovascular event risk assessment in
psoriasis patients treated with tumor necrosis factor-α inhibitors
versus methotrexate. J Am Acad Dermatol. 76:81–90. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wu JJ, Sundaram M, Cloutier M,
Gauthier-Loiselle M, Guérin A, Singh R and Ganguli A: The risk of
cardiovascular events in psoriasis patients treated with tumor
necrosis factor-α inhibitors versus phototherapy: An observational
cohort study. J Am Acad Dermatol. 79:60–68. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Gkalpakiotis S, Arenbergerova M,
Gkalpakioti P, Potockova J, Arenberger P and Kraml P: Impact of
adalimumab treatment on cardiovascular risk biomarkers in
psoriasis: Results of a pilot study. J Dermatol. 44:363–369.
2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Kovitwanichkanont T, Chong AH and Foley P:
Beyond skin deep: Addressing comorbidities in psoriasis. Med J
Aust. 212:528–534. 2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Gelfand JM, Shin DB, Alavi A, Torigian DA,
Werner T, Papadopoulos M, Takeshita J, Noe MH, Dey AK, Playford MP
and Mehta NN: A Phase IV, randomized, double-blind,
placebo-controlled crossover study of the effects of ustekinumab on
vascular inflammation in psoriasis (the VIP-U Trial). J Invest
Dermatol. 140:85–93.e2. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Poizeau F, Nowak E, Kerbrat S, Le Nautout
B, Droitcourt C, Drici MD, Sbidian E, Guillot B, Bachelez H,
Ait-Oufella H, et al: Association between early severe
cardiovascular events and the initiation of treatment with the
anti-interleukin 12/23p40 antibody Ustekinumab. JAMA Dermatol.
156:1208–1215. 2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lee MP, Desai RJ, Jin Y, Brill G, Ogdie A
and Kim SC: Association of Ustekinumab vs. TNF inhibitor therapy
with risk of atrial fibrillation and cardiovascular events in
patients with psoriasis or psoriatic arthritis. JAMA Dermatol.
155:700–707. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ait-Oufella H, Libby P and Tedgui A:
Anticytokine immune therapy and atherothrombotic cardiovascular
risk. Arterioscler Thromb Vasc Biol. 39:1510–1519. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Thatiparthi A, Martin A, Liu J, Egeberg A
and Wu JJ: Biologic treatment algorithms for moderate-to-severe
psoriasis with comorbid conditions and special populations: A
review. Am J Clin Dermatol. 22:425–442. 2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Nast A, Smith C, Spuls PI, Avila Valle G,
Bata-Csörgö Z, Boonen H, De Jong E, Garcia-Doval I, Gisondi P,
Kaur-Knudsen D, et al: EuroGuiDerm Guideline on the systemic
treatment of psoriasis vulgaris-Part 2: Specific clinical and
comorbid situations. J Eur Acad Dermatol Venereol. 35:281–317.
2021.PubMed/NCBI View Article : Google Scholar
|
